Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Free Tissue Flaps | 7 | 2024 | 49 | 2.270 |
Why?
|
| Mandibular Reconstruction | 2 | 2024 | 10 | 1.510 |
Why?
|
| Head and Neck Neoplasms | 13 | 2026 | 637 | 1.410 |
Why?
|
| Veterans | 6 | 2025 | 1805 | 1.220 |
Why?
|
| Laryngeal Neoplasms | 4 | 2023 | 86 | 1.070 |
Why?
|
| Osteoradionecrosis | 2 | 2023 | 18 | 0.960 |
Why?
|
| Adenolymphoma | 1 | 2025 | 4 | 0.940 |
Why?
|
| Parotid Neoplasms | 1 | 2025 | 22 | 0.930 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2022 | 265 | 0.910 |
Why?
|
| Tongue Neoplasms | 2 | 2023 | 30 | 0.890 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2023 | 754 | 0.870 |
Why?
|
| Mandibular Osteotomy | 1 | 2024 | 7 | 0.850 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 2 | 2021 | 35 | 0.790 |
Why?
|
| Pregnancy Tests | 1 | 2023 | 1 | 0.780 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2023 | 20 | 0.770 |
Why?
|
| Mouth Neoplasms | 1 | 2023 | 99 | 0.690 |
Why?
|
| Scapula | 1 | 2021 | 16 | 0.670 |
Why?
|
| Mouth | 1 | 2021 | 64 | 0.660 |
Why?
|
| Cephalometry | 1 | 2021 | 46 | 0.660 |
Why?
|
| Veterans Health | 1 | 2021 | 172 | 0.620 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 1311 | 0.610 |
Why?
|
| Minority Groups | 1 | 2020 | 258 | 0.540 |
Why?
|
| Prostatic Neoplasms | 5 | 2024 | 1414 | 0.460 |
Why?
|
| Postoperative Complications | 4 | 2024 | 3131 | 0.440 |
Why?
|
| Mandible | 3 | 2024 | 97 | 0.420 |
Why?
|
| Retrospective Studies | 20 | 2026 | 17673 | 0.420 |
Why?
|
| Laryngectomy | 3 | 2023 | 32 | 0.380 |
Why?
|
| Prostatectomy | 5 | 2024 | 300 | 0.380 |
Why?
|
| Middle Aged | 20 | 2025 | 28517 | 0.370 |
Why?
|
| Aged | 15 | 2025 | 20974 | 0.350 |
Why?
|
| Postoperative Care | 2 | 2025 | 297 | 0.310 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 1234 | 0.290 |
Why?
|
| Humans | 36 | 2026 | 130870 | 0.280 |
Why?
|
| Graft Survival | 2 | 2021 | 462 | 0.260 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2026 | 6 | 0.250 |
Why?
|
| Enterobacteriaceae | 1 | 2026 | 40 | 0.240 |
Why?
|
| Carbapenems | 1 | 2026 | 45 | 0.240 |
Why?
|
| Time-to-Treatment | 2 | 2025 | 210 | 0.240 |
Why?
|
| Disease-Free Survival | 4 | 2020 | 904 | 0.240 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2025 | 9 | 0.240 |
Why?
|
| Male | 21 | 2025 | 64772 | 0.230 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2025 | 107 | 0.230 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2025 | 157 | 0.230 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 385 | 0.230 |
Why?
|
| Female | 17 | 2025 | 70560 | 0.220 |
Why?
|
| Mandibular Neoplasms | 1 | 2024 | 9 | 0.210 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 6801 | 0.200 |
Why?
|
| Clinical Competence | 2 | 2015 | 1055 | 0.200 |
Why?
|
| Adult | 9 | 2025 | 31245 | 0.200 |
Why?
|
| T-Lymphocytes | 2 | 2026 | 1713 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 632 | 0.200 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2026 | 396 | 0.200 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2023 | 26 | 0.190 |
Why?
|
| Maxillofacial Injuries | 1 | 2022 | 9 | 0.190 |
Why?
|
| Maxillary Fractures | 1 | 2022 | 12 | 0.190 |
Why?
|
| Chorionic Gonadotropin | 1 | 2023 | 77 | 0.190 |
Why?
|
| Single-Cell Analysis | 1 | 2026 | 358 | 0.190 |
Why?
|
| Head | 1 | 2023 | 109 | 0.180 |
Why?
|
| Machine Learning | 1 | 2026 | 386 | 0.180 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2026 | 499 | 0.180 |
Why?
|
| Larynx | 1 | 2023 | 73 | 0.180 |
Why?
|
| Orbital Fractures | 1 | 2022 | 39 | 0.180 |
Why?
|
| Eye Injuries | 1 | 2022 | 49 | 0.180 |
Why?
|
| Glossectomy | 1 | 2021 | 7 | 0.180 |
Why?
|
| Metformin | 1 | 2023 | 171 | 0.170 |
Why?
|
| Organ Transplantation | 1 | 2023 | 170 | 0.170 |
Why?
|
| Wounds, Gunshot | 1 | 2022 | 146 | 0.170 |
Why?
|
| Mechanical Thrombolysis | 1 | 2020 | 10 | 0.170 |
Why?
|
| Pharyngeal Diseases | 1 | 2020 | 18 | 0.160 |
Why?
|
| Papillomaviridae | 2 | 2022 | 179 | 0.160 |
Why?
|
| Cutaneous Fistula | 1 | 2020 | 21 | 0.160 |
Why?
|
| Smoking | 1 | 2025 | 923 | 0.160 |
Why?
|
| Survival Rate | 3 | 2020 | 2140 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 694 | 0.150 |
Why?
|
| Risk | 1 | 2021 | 729 | 0.150 |
Why?
|
| Gastrostomy | 1 | 2019 | 86 | 0.150 |
Why?
|
| Recovery of Function | 1 | 2021 | 446 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 1279 | 0.140 |
Why?
|
| Length of Stay | 1 | 2024 | 1396 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2019 | 3694 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2021 | 813 | 0.130 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 136 | 0.130 |
Why?
|
| Microvessels | 1 | 2018 | 59 | 0.130 |
Why?
|
| Synthetic Lethal Mutations | 1 | 2017 | 11 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 114 | 0.130 |
Why?
|
| Treatment Outcome | 6 | 2023 | 12914 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 145 | 0.120 |
Why?
|
| Lurasidone Hydrochloride | 1 | 2016 | 3 | 0.120 |
Why?
|
| Irritable Mood | 1 | 2016 | 9 | 0.120 |
Why?
|
| Internship and Residency | 2 | 2017 | 1216 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 901 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 265 | 0.120 |
Why?
|
| Disease Management | 1 | 2019 | 559 | 0.110 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 372 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1290 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2026 | 2565 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 5199 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 499 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2025 | 6450 | 0.100 |
Why?
|
| Prostate | 2 | 2007 | 410 | 0.100 |
Why?
|
| Nasal Provocation Tests | 1 | 2013 | 1 | 0.100 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2013 | 9 | 0.100 |
Why?
|
| Antigens, Fungal | 1 | 2013 | 31 | 0.100 |
Why?
|
| Antipsychotic Agents | 1 | 2016 | 364 | 0.090 |
Why?
|
| Stroke | 1 | 2020 | 1058 | 0.090 |
Why?
|
| Autistic Disorder | 1 | 2016 | 395 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 1548 | 0.090 |
Why?
|
| Computational Biology | 1 | 2017 | 868 | 0.090 |
Why?
|
| Texas | 1 | 2020 | 3635 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 575 | 0.090 |
Why?
|
| Salvage Therapy | 2 | 2023 | 175 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 2 | 2008 | 227 | 0.080 |
Why?
|
| Pregnancy | 1 | 2023 | 7402 | 0.080 |
Why?
|
| Algorithms | 1 | 2017 | 1682 | 0.080 |
Why?
|
| Prognosis | 4 | 2022 | 4913 | 0.070 |
Why?
|
| Iatrogenic Disease | 1 | 2007 | 119 | 0.060 |
Why?
|
| Klebsiella | 1 | 2026 | 11 | 0.060 |
Why?
|
| Precision Medicine | 2 | 2022 | 386 | 0.060 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2026 | 58 | 0.060 |
Why?
|
| Skull Base | 1 | 2024 | 50 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2024 | 229 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2026 | 846 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2024 | 277 | 0.050 |
Why?
|
| General Surgery | 1 | 2005 | 225 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2022 | 117 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 2925 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2026 | 702 | 0.040 |
Why?
|
| Neck | 1 | 2022 | 142 | 0.040 |
Why?
|
| Pharyngectomy | 1 | 2020 | 6 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2026 | 995 | 0.040 |
Why?
|
| Contrast Media | 1 | 2024 | 491 | 0.040 |
Why?
|
| Risk Factors | 4 | 2019 | 10978 | 0.040 |
Why?
|
| Glottis | 1 | 2019 | 29 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 2020 | 160 | 0.040 |
Why?
|
| Deglutition | 1 | 2019 | 55 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 420 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 260 | 0.040 |
Why?
|
| Adolescent | 3 | 2023 | 20820 | 0.040 |
Why?
|
| Comorbidity | 1 | 2022 | 1587 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 208 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 257 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 360 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2017 | 185 | 0.030 |
Why?
|
| Time Factors | 1 | 2025 | 6217 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 494 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 667 | 0.030 |
Why?
|
| Reference Values | 1 | 2015 | 680 | 0.030 |
Why?
|
| Propensity Score | 1 | 2015 | 272 | 0.030 |
Why?
|
| United States | 2 | 2019 | 11865 | 0.030 |
Why?
|
| Alternaria | 1 | 2013 | 3 | 0.020 |
Why?
|
| Aspergillus | 1 | 2013 | 26 | 0.020 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 536 | 0.020 |
Why?
|
| Rhinitis, Allergic | 1 | 2013 | 18 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 1215 | 0.020 |
Why?
|
| Skin Tests | 1 | 2013 | 95 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1380 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 3827 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1892 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 607 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1805 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2018 | 3393 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 551 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 3727 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 3807 | 0.020 |
Why?
|
| Young Adult | 1 | 2022 | 10042 | 0.020 |
Why?
|
| California | 1 | 2008 | 127 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 2007 | 27 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 5095 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 2212 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 18268 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 1617 | 0.010 |
Why?
|
| Animals | 1 | 2017 | 33982 | 0.010 |
Why?
|
| Child | 1 | 2016 | 26218 | 0.010 |
Why?
|